Clinical Trial Update: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody in relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMAxCD3 Bispecific Antibody
• JNJ-79635322

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING